Group 1 - The core announcement is that CAI Holdings (00080.HK) has confirmed the expiration of its 2015 Share Option Scheme on May 31, 2025, after which no further options can be granted under this scheme [1] - The board of directors has proposed to adopt a new 2025 Share Scheme in accordance with Listing Rule Chapter 17, aimed at incentivizing eligible participants for their contributions to the company's growth and development [1] - There are no unexercised options remaining under the 2015 Share Option Scheme as of the date of the announcement [1]

Group 1 - The core point of the article is that Jinxin Reproductive Medicine (01951) has proposed a 2025 Share Option Plan, which aims to align the long-term interests of the company's directors and key employees with those of the company, thereby incentivizing them to drive growth and development [1] - The 2025 Share Option Plan will constitute a share option scheme funded through the issuance of new shares, in accordance with Chapter 17 of the Listing Rules [1] - On September 25, 2025, the board resolved to grant a total of 137,235,000 share options to the management under the 2025 Share Option Plan, subject to conditional approval from independent shareholders at a special general meeting [1] Group 2 - Additionally, the board plans to grant a total of 2,400,000 share options and 1,200,000 restricted shares to non-executive participants under the 2025 Share Option Plan [1]

Group 1 - The core point of the article is that Jinxin Reproductive (01951.HK) announced a proposal for a 2025 share plan, which aims to align the long-term interests of the company's directors and key employees with those of the company and incentivize them to drive growth and development [1] Group 2 - The 2025 share plan will constitute a share scheme funded through the issuance of new shares, in accordance with Chapter 17 of the listing rules [1] - On September 25, 2025, contingent upon the effectiveness of the 2025 share plan, the board resolved to grant a total of 137,235,000 stock options to the management, with conditional grants to Dong Yang pending approval at a special general meeting of independent shareholders [1] - Additionally, the board decided to grant a total of 2,400,000 stock options and 1,200,000 restricted shares to non-executive grantees under the 2025 share plan [1]